Report an error   


Submitted: 28 February 2017 Modified: 09 March 2017
HERDIN Record #: PCHRD17022814150112

Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period.

Maria Rosario Capeding,
Thelma  M. Laot,
Mark  Boaz,
T. Anh Wartel,
Denis Crevat

See More

This study assessed the safety and persistence of dengue neutralising antibodies for five years after administration of a recombinant live, attenuated, tetravalent dengue vaccine (TDV). Participants aged 2-45 years (n = 126) were randomised at a single centre in the Philippines to receive TDV vaccinations at months 0, 3-4, and 12 (TDV-TDV-TDV group) or licensed typhoid vaccination (TyVi) at month 0 and TDV at months 3-4 and 12 (TyVi-TDV-TDV group). Dengue antibodies were measured annually (plaque reduction neutralisation test). Participants with suspected dengue underwent laboratory testing. No safety concerns were reported throughout the study. Six dengue cases were virologically confirmed, but assessed as non-severe dengue disease. Geometric mean titres throughout the follow-up period remained 2- to 4-fold higher than at baseline for all serotypes, ages and study groups. Approximately 10% of participants annually were exposed to wild-type dengue, which contributed to persistently higher titres compared with non-infected participants. In conclusion, TDV appears to have good safety and persistence of antibodies over five years.

Publication Type
Journal
Publication Sub Type
Journal Article, Original
Title
Trials in Vaccinology
Publication Date
2015
Volume
4
Page(s)
19–23
LocationLocation CodeAvailable FormatAvailability
Science Direct Website Abstract External Link (View)